InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright BioConnect Conference

Rhea-AI Summary

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a clinical-stage biotechnology company focused on spinal cord injury treatments, announced that CEO Richard Toselli will present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022. The presentation will offer insights into the company's developments and clinical programs. Attendees can access the webcast starting January 10 at 7:00 am ET and participate in one-on-one meetings with management. Founded in 2005, InVivo utilizes proprietary technology co-invented by renowned researchers from MIT and Boston Children's Hospital.

Positive

• CEO will present at a notable conference, potentially enhancing visibility.
• Opportunity for one-on-one meetings with company management for investors.

Negative

• None.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming virtual H.C. Wainwright BioConnect Conference, which runs from January 10 – 13, 2022. Dr. Toselli’s presentation will provide an overview of the company and will also highlight recent updates to the company’s clinical program.

A webcast of Dr. Toselli’s presentation will be available on the Investor Relations - Events section of the company website at https://investors.invivotherapeutics.com/events, beginning January 10, 2022 at 7:00 am ET. Dr. Toselli and company management will also be available to participate in one-on-one meetings with registered investors attending the conference.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. The publicly traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005150/en/

Investor:



Bret Shapiro, Managing Partner

CORE IR

brets@coreir.com

(516) 222-2560

Media:



Gina Nugent

Ten Bridge Communications

gina@tenbridgecommunications.com

617-460-3579

Source: InVivo Therapeutics Holdings Corp.

FAQ

What is InVivo Therapeutics Holdings Corp. known for?

InVivo Therapeutics is a clinical-stage biotechnology company focusing on treatments for spinal cord injuries.

When is the H.C. Wainwright BioConnect Conference taking place?

The conference runs from January 10 to 13, 2022.

Who is presenting for InVivo at the conference?

Richard Toselli, M.D., the President and CEO, will be presenting.

How can investors access the presentation from InVivo?

The presentation will be available as a webcast on the company's Investor Relations page starting January 10, 2022, at 7:00 am ET.

What significant updates will be discussed in the presentation?

The presentation will highlight recent updates to InVivo's clinical program.